We transform critical care medicine by developing innovative and effective therapies based on alkaline phosphatase (RESCAP®). We are guided by our core values of loyalty towards relationships, accuracy, and high scientific commitment, which underpin everything we do.
Our goal is to create a positive impact on the world by bringing new hope to patients and their families through safe, effective, and accessible treatments that improve outcomes and enhance quality of life.
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
And gain exclusive access to the latest news, updates, and insights from our team of experts.
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall
APPIRED III study is getting well on its way with 9 centres started with including patients. These centres are Singapore NUH, CZE Eindhoven, Jessa, Hasselt,
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.
